Bioatla announces regulatory update on clinical development plan for ozuriftamab vedotin in oropharyngeal squamous cell carcinoma (opscc) following productive type b (end of phase 2) meeting with fda

Fda alignment on phase 3 ozuriftamab vedotin (oz-v) trial design, including dosing regimen and endpoints to support potential accelerated approval company continues preparations for enabling initiation of the phase 3 study with the goal of advancing the study with a strategic partner early next year company maintains previous guidance for completion of a strategic partnership with one of our advanced clinical assets this year san diego, sept. 08, 2025 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics using its proprietary cab platform for the treatment of solid tumors, today announced outcomes from its type b meeting with the united states food and drug administration (fda).
BCAB Ratings Summary
BCAB Quant Ranking